{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Yang S"],"funding":["HMRF"],"pagination":["344"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5437682"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["17(1)"],"pubmed_abstract":["<h4>Background</h4>DNA repair pathways are used by cancer cells to overcome many standard anticancer treatments, causing therapy resistance. Here, we investigated the role of XRCC4-like factor (XLF), a core member of the non-homologous end joining (NHEJ) repair pathway, in chemoresistance in hepatocellular carcinoma (HCC).<h4>Methods</h4>qRT-PCR analysis and western blotting were performed to detect expression levels of genes and proteins related to NHEJ. NHEJ repair capacity was assessed in vitro (cell-free) and in vivo by monitoring the activity of the NHEJ pathway. Cell viability and IC50 assays were used to measure sensitivity to drug therapy. A xenograft HCC model was used to develop methods of targeting XLF-induced chemosensitization. Clinicopathological analysis was conducted on pat"],"journal":["BMC cancer"],"pubmed_title":["XLF-mediated NHEJ activity in hepatocellular carcinoma therapy resistance."],"pmcid":["PMC5437682"],"funding_grant_id":["03143396"],"pubmed_authors":["Wang XQ","Yang S"],"additional_accession":[]},"is_claimable":false,"name":"XLF-mediated NHEJ activity in hepatocellular carcinoma therapy resistance.","description":"<h4>Background</h4>DNA repair pathways are used by cancer cells to overcome many standard anticancer treatments, causing therapy resistance. Here, we investigated the role of XRCC4-like factor (XLF), a core member of the non-homologous end joining (NHEJ) repair pathway, in chemoresistance in hepatocellular carcinoma (HCC).<h4>Methods</h4>qRT-PCR analysis and western blotting were performed to detect expression levels of genes and proteins related to NHEJ. NHEJ repair capacity was assessed in vitro (cell-free) and in vivo by monitoring the activity of the NHEJ pathway. Cell viability and IC50 assays were used to measure sensitivity to drug therapy. A xenograft HCC model was used to develop methods of targeting XLF-induced chemosensitization. Clinicopathological analysis was conducted on pat","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017 May","modification":"2025-04-19T19:07:00.229Z","creation":"2019-03-27T02:45:26Z"},"accession":"S-EPMC5437682","cross_references":{"pubmed":["28526069"],"doi":["10.1186/s12885-017-3345-y"]}}